females to follow finalist
RISING STAR IN INDUSTRY
Bahar Ramezanpour
CBO
HUB Organoids
About Bahar Ramezanpour
Bahar Ramezanpour, Ph.D., holds a doctorate in disruptive innovation by genetically modified technologies from the University of Amsterdam and Erasmus University Rotterdam. She joined HUB Organoids in 2017, bringing strong commercial experience from a range of business development roles, combined with a strong scientific background in infectious diseases and vaccines development, offering a unique blend of commercial insight and technological expertise.
At HUB Organoids, Bahar played a central role in business development and strategic growth, contributing to the company’s expansion and its acquisition by Merck KGaA Life Science. Her work has supported the advancement of patient-derived organoid technology and the company’s position in the global life sciences sector.
About HUB Organoids
HUB Organoids is a leader in patient-derived organoid technology, offering contract research services for drug discovery and development based on a proprietary biobank of organoid models. The company’s platform enables the growth of genetically stable organoids from both healthy and diseased tissues, providing predictive preclinical models for oncology, inflammatory diseases, genetic disorders, and more. With a strong focus on scientific validation, quality control, and global partnerships, HUB Organoids supports biopharma clients in accelerating drug development and advancing personalized medicine.
HUB Organoids is a leader in patient-derived organoid technology, offering contract research services for drug discovery and development based on a proprietary biobank of organoid models. The company’s platform enables the growth of genetically stable organoids from both healthy and diseased tissues, providing predictive preclinical models for oncology, inflammatory diseases, genetic disorders, and more. With a strong focus on scientific validation, quality control, and global partnerships, HUB Organoids supports biopharma clients in accelerating drug development and advancing personalized medicine.
| Powered by: Hyphen Projects BV | Connect with us | Join TOPX | |||
| Privacy Policy Terms & Conditions Chamber of Commerce: 32110979 VAT no: NL8184.34.491.B01 | | |
© Copyright 2020 by Hyphen Projects